Clinical Trial Update: Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006 [Phase 2]

View source ↗

Summary

A Phase 2 follow-up study evaluating continued AFFITOPE AD02 vaccinations in Alzheimer's disease participants has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• AFFITOPE AD02 (AD02)

Snippet

Sponsor: Affiris AG | Conditions: Alzheimer´s Disease | Phase 2 | Status: TERMINATED